Wednesday, July 10, 2013

Mallinckrodt plc to Report Third Quarter Results on August 9, 2013

DUBLIN - Wednesday, July 10th 2013 [ME NewsWire]

(BUSINESS WIRE) Mallinckrodt plc (NYSE: MNK) will report third quarter results on August 9, 2013, before trading opens for the day on the New York Stock Exchange. The company will hold a conference call for investors beginning at 8:30am/U.S. Eastern Daylight Time. The call can be accessed in three ways.

    At the Mallinckrodt website:
    By telephone: For both “listen-only” participants and those who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-415- 3182. For participants outside the U.S., the dial-in number is 857-244-7325. The access code for all callers is 44964726.
    Through an audio replay: A replay of the call will be available beginning at 10:30am/ U.S. Eastern Daylight Time on August 9, 2013, and ending at 11:59pm/ U.S. Eastern Daylight Time on August 23, 2013. The dial-in number for U.S. participants is 888-286-8010. For participants outside the U.S., the replay dial-in number is 617- 801-6888. The replay access code for all callers is 51646528.


Mallinckrodt is a leading global specialty pharmaceuticals business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents with the highest quality standards and care. The company’s Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide with direct sales in roughly 50 countries and distribution in approximately 40 countries. The company’s 2012 revenue totaled $2.1 billion. To learn more about Mallinckrodt, visit


Mallinckrodt plc

John Moten, 314-654-6650

Vice President, Investor Relations

Lynn Phillips, 314-654-3263

Manager, Media Relations

Meredith Fischer, 314-654-6595

Senior Vice President, Communications

No comments:

Post a Comment